

PRACTICE GUIDELINE

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease



A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons

Writing Committee Members*

Rick A. Nishimura, MD, MACC, FAHA,
Co-Chair[†]
Catherine M. Otto, MD, FACC, FAHA,
Co-Chair[†]

Robert O. Bonow, MD, MACC, FAHA[†]
Blase A. Carabello, MD, FACC^{*†}
John P. Erwin III, MD, FACC, FAHA[‡]
Robert A. Guyton, MD, FACC^{*§}
Patrick T. O'Gara, MD, FACC, FAHA[†]
Carlos E. Ruiz, MD, PhD, FACC[†]
Nikolaos J. Skubas, MD, FASE[¶]

Paul Sorajja, MD, FACC, FAHA[#]
Thoralf M. Sundt III, MD^{* **††}
James D. Thomas, MD, FASE, FACC, FAHA^{‡‡}

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see [Appendix 1](#) for recusal information. [†]ACC/AHA representative. [‡]ACC/AHA Task Force on Performance Measures liaison. [§]ACC/AHA Task Force on Practice Guidelines liaison. [¶]Society of Cardiovascular Anesthesiologists representative. [#]Society for Cardiovascular Angiography and Interventions representative. ^{**}American Association for Thoracic Surgery representative. ^{††}Society of Thoracic Surgeons representative. ^{‡‡}American Society of Echocardiography representative.

ACC/AHA Task Force Members

Jeffrey L. Anderson, MD, FACC, FAHA,
Chair
Jonathan L. Halperin, MD, FACC, FAHA,
Chair-Elect

Nancy M. Albert, PhD, CCNS, CCRN, FAHA
Biykem Bozkurt, MD, PhD, FACC, FAHA
Ralph G. Brindis, MD, MPH, MACC
Mark A. Creager, MD, FACC, FAHA^{§§}
Lesley H. Curtis, PhD, FAHA
David DeMets, PhD

Robert A. Guyton, MD, FACC^{§§}
Judith S. Hochman, MD, FACC, FAHA
Richard J. Kovacs, MD, FACC, FAHA
E. Magnus Ohman, MD, FACC
Susan J. Pressler, PhD, RN, FAHA
Frank W. Sellke, MD, FACC, FAHA
Win-Kuang Shen, MD, FACC, FAHA
William G. Stevenson, MD, FACC, FAHA^{§§}
Clyde W. Yancy, MD, FACC, FAHA^{§§}

^{§§}Former Task Force member during the writing effort.

This document was approved by the American College of Cardiology Board of Trustees and the American Heart Association Science Advisory and Coordinating Committee in January 2014.

The American College of Cardiology requests that this document be cited as follows: Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;63:e57–185.

This article has been copublished in *Circulation*.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org) and the American Heart Association (my.americanheart.org). For copies of this document, please contact the Elsevier Inc. Reprint Department via fax (212) 633–3820 or e-mail reprints@elsevier.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology. Requests may be completed online via the Elsevier site (<http://www.elsevier.com/authors/obtaining-permission-to-re-use-elsevier-material>).

TABLE OF CONTENTS

Preamble	e60
1. Introduction	e62
1.1. Methodology and Evidence Review	e62
1.2. Organization of the Writing Committee	e62
1.3. Document Review and Approval	e62
1.4. Scope of the Guideline	e62
2. General Principles	e63
2.1. Evaluation of the Patient With Suspected VHD	e63
2.2. Definitions of Severity of Valve Disease	e64
2.3. Diagnosis and Follow-Up	e64
2.3.1. Diagnostic Testing—Initial Diagnosis: Recommendation	e64
2.3.2. Diagnostic Testing—Changing Signs or Symptoms: Recommendation	e65
2.3.3. Diagnostic Testing—Routine Follow-Up: Recommendation	e65
2.3.4. Diagnostic Testing—Cardiac Catheterization: Recommendation	e65
2.3.5. Diagnostic Testing—Exercise Testing: Recommendation	e65
2.4. Basic Principles of Medical Therapy	e66
2.4.1. Secondary Prevention of Rheumatic Fever: Recommendation	e66
2.4.2. IE Prophylaxis: Recommendations	e67
2.5. Evaluation of Surgical and Interventional Risk	e68
2.6. The Heart Valve Team and Heart Valve Centers of Excellence: Recommendations	e69
3. Aortic Stenosis	e71
3.1. Stages of Valvular AS	e71
3.2. Aortic Stenosis	e71
3.2.1. Diagnosis and Follow-Up	e71
3.2.1.1. DIAGNOSTIC TESTING—INITIAL DIAGNOSIS: RECOMMENDATIONS	e71
3.2.1.2. DIAGNOSTIC TESTING—CHANGING SIGNS OR SYMPTOMS	e73
3.2.1.3. DIAGNOSTIC TESTING—ROUTINE FOLLOW-UP	e73
3.2.1.4. DIAGNOSTIC TESTING—CARDIAC CATHETERIZATION	e73
3.2.1.5. DIAGNOSTIC TESTING—EXERCISE TESTING: RECOMMENDATIONS	e74
3.2.2. Medical Therapy: Recommendations	e74
3.2.3. Timing of Intervention: Recommendations	e75
3.2.4. Choice of Intervention: Recommendation	e79
4. Aortic Regurgitation	e82
4.1. Acute AR	e82
4.1.1. Diagnosis	e83
4.1.2. Intervention	e83
4.2. Stages of Chronic AR	e83
4.3. Chronic AR	e83

4.3.1. Diagnosis and Follow-Up	e83
4.3.1.1. DIAGNOSTIC TESTING—INITIAL DIAGNOSIS: RECOMMENDATIONS	e83
4.3.1.2. DIAGNOSTIC TESTING—CHANGING SIGNS OR SYMPTOMS	e85
4.3.1.3. DIAGNOSTIC TESTING—ROUTINE FOLLOW-UP	e85
4.3.1.4. DIAGNOSTIC TESTING—CARDIAC CATHETERIZATION	e85
4.3.1.5. DIAGNOSTIC TESTING—EXERCISE TESTING	e85
4.3.2. Medical Therapy: Recommendations	e85
4.3.3. Timing of Intervention: Recommendations	e86
5. Bicuspid Aortic Valve and Aortopathy	e88
5.1. Bicuspid Aortic Valve	e88
5.1.1. Diagnosis and Follow-Up	e88
5.1.1.1. DIAGNOSTIC TESTING—INITIAL DIAGNOSIS: RECOMMENDATIONS	e88
5.1.1.2. DIAGNOSTIC TESTING—ROUTINE FOLLOW-UP: RECOMMENDATION	e89
5.1.2. Medical Therapy	e89
5.1.3. Intervention: Recommendations	e89
6. Mitral Stenosis	e90
6.1. Stages of MS	e90
6.2. Rheumatic MS	e90
6.2.1. Diagnosis and Follow-Up	e90
6.2.1.1. DIAGNOSTIC TESTING—INITIAL DIAGNOSIS: RECOMMENDATIONS	e90
6.2.1.2. DIAGNOSTIC TESTING—CHANGING SIGNS OR SYMPTOMS	e91
6.2.1.3. DIAGNOSTIC TESTING—ROUTINE FOLLOW-UP	e91
6.2.1.4. DIAGNOSTIC TESTING—CARDIAC CATHETERIZATION	e92
6.2.1.5. DIAGNOSTIC TESTING—EXERCISE TESTING: RECOMMENDATION	e93
6.2.2. Medical Therapy: Recommendations	e93
6.2.3. Intervention: Recommendations	e94
6.3. Nonrheumatic MS	e96
7. Mitral Regurgitation	e97
7.1. Acute MR	e97
7.1.1. Diagnosis and Follow-Up	e97
7.1.2. Medical Therapy	e97
7.1.3. Intervention	e98
7.2. Stages of Chronic MR	e98
7.3. Chronic Primary MR	e98
7.3.1. Diagnosis and Follow-Up	e98
7.3.1.1. DIAGNOSTIC TESTING—INITIAL DIAGNOSIS: RECOMMENDATIONS	e98
7.3.1.2. DIAGNOSTIC TESTING—CHANGING SIGNS OR SYMPTOMS	e101
7.3.1.3. DIAGNOSTIC TESTING—ROUTINE FOLLOW-UP	e101
7.3.1.4. DIAGNOSTIC TESTING—CARDIAC CATHETERIZATION	e101
7.3.1.5. DIAGNOSTIC TESTING—EXERCISE TESTING: RECOMMENDATIONS	e102
7.3.2. Medical Therapy: Recommendations	e102
7.3.3. Intervention: Recommendations	e102
7.4. Chronic Secondary MR	e106
7.4.1. Diagnosis and Follow-Up: Recommendations	e106
7.4.2. Medical Therapy: Recommendations	e106
7.4.3. Intervention: Recommendations	e107

Download English Version:

<https://daneshyari.com/en/article/2945399>

Download Persian Version:

<https://daneshyari.com/article/2945399>

[Daneshyari.com](https://daneshyari.com)